Recent progress in understanding the pathogenesis of immune thrombocytopenia

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 590-595

  Semple, John W ^a,b,c,d,e   Provan, Drew ^f   Garvey, M Bernadette ^a,b,c,d,e   Freedman, John ^a,b,c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Department of Pharmacology ^*  (Canada)

^c Department of Brain Sciences   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Toronto Platelet Immunobiology Group   (Canada)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

B lymphocytes; cytokines; immune thrombocytopenia; platelets; T lymphocytes

Indexed keywords

B CELL ACTIVATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 18; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN PRESENTING CELL; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; DNA POLYMORPHISM; GENETIC ANALYSIS; HUMAN; MOLECULAR MIMICRY; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; THROMBOCYTE; THROMBOCYTOPOIESIS;

BLOOD PLATELETS; HUMANS; T-LYMPHOCYTES; THROMBOCYTOPENIA;

EID: 78049291385     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833eaef3     Document Type: Review

References (74)

1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-186.
2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386-2393.
3. Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur J Haematol 2009; Suppl 71:8-12.
4. Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol-Oncol Clin N Am 2009; 23:1193-1211.
5. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009; 113:3154-3160.
6. Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113:6511-6521.
7. Semple JW. Infections, antigen-presenting cells, T cells, and immune tolerance: their role in the pathogenesis of immune thrombocytopenia. Hematol-Oncol Clin N Am 2009; 23:1177-1192.
8. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol-Oncol Clin N Am 2009; 23:1163-1175.
9. Godeau B. Immune thrombocytopenic purpura: pathophysiology and treatment. Transfus Clin et Biol 2009; 16:101-105.
10. Chong BH. Primary immune thrombocytopenia: understanding pathogenesis is the key to better treatments. J Thromb Haemost 2009; 7:319-321.
11. Gernsheimer TB. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 2009; 14:12-21.
12. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematol 2009; 1:153-158.
13. Zhang W, Nardi MA, Borkowsky W, et al. Role of molecular mimicry of HCV protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 2009; 113:4086-4093. This study showed that, like HIV, HCV infection associated with ITP induces antiplatelet antibodies with the same specificity (aa-49-66).
14. Li Z, Nardi MA, Wu J, et al. Platelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin. J Biol Chem 2009; 283:3224-3230.
15. Peterson JA, Nelson TN, Kanack AJ, et al. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood 2008; 111:1234-1239.
16. Aster RH. Molecular mimicry and immune thrombocytopenia. Blood 2009; 113:3887-3888.
17. Wang CM, Sheng GY, Zou X, et al. Levels of Toll-like receptors-2,-4 on platelets in children with idiopathic thrombocytopenic purpura. Zhongguo Dangdai Erke Zazhi 2009; 11:797-801.
18. Wan YY. Regulatory T cells: immune suppression and beyond. Cell Mol Immunol 2010; 7:204-210.
19. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140:845-858.
20. Sakakura M, Wada H, Tawara I, et al. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2009; 120:187-193.
21. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasone. Eur J Haematol 2009; 79:310-316.
22. Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(+) CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2009; 78:139-143.
23. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatoryT cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 2009; 112:1147-1150.
24. Olsson B, Ridell B, Carlsson L, et al. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2009; 12:1078-1084.
25. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2009; 112:1325-1328.
26. Shu MM, Cao XM, Zhang WG. Role of CD4(+) CD25(high) T cells in the pathogenesis of idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16:875-877.
27. Zhang X-L, Peng J, Sun J-Z, et al. De novo induction of platelet-specific CD4-CD25- regulatory T cells from CD4-CD25- cells in patients with idiopathic thrombocytopenic purpura. Blood 2009; 113:2568-2577.
28. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9:1123-1124.
29. Zhao C, Li X, Zhang F, et al. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008; 93:1428-1430.
30. Chow L, Speck ER, Kim M, et al. A novel mouse model demonstrating both antibody-and T cell-mediated thrombocytopenia: differential response to IVIG. Blood 2010; 115:1247-1253.
31. Sabnani I,Tsang P. Therapeutic implications of T-cell clonopathy of unknown significance in chronic immune thrombocytopenic purpura. Platelets 2009; 20:135-139.
32. Zhang XL, Li YQ, Chen SH, et al. The feature of clonal expansion of TCR Vbeta repertoire, thymic recent output function and TCRzeta chain expression in patients with immune thrombocytopenic purpura. Int J Lab Hematol 2009; 31:639-648.
33. Zhang X, Chen S, Yang L, et al. The feature of TRGV and TRDV repertoire distribution and clonality in patients with immune thrombocytopenic purpura. Hematology 2009; 14:237-244.
34. Du WT, Zhao HF, Xu JH, et al. The role of T-cell immunoglobulin-and mucin-domain-containing molecule-3 polymorphisms in idiopathic thrombocytopenic purpura. Hum Immunol 2009; 70:398-402.
35. Zhong YG, Feng WY, Luo HQ, et al. Fas-FasL and caspase-3 signal transduction pathway and apoptosis of peripheral T lymphocytes in ITP patients. Chinese J Hematol 2008; 29:329-332.
36. Lopez-Karpovitch X, Graue G, Crespo-Solis E, Piedras J. Multidrug resistance-1 in T lymphocytes and natural killer cells of adults with idiopathic thrombocytopenic purpura: effect of prednisone treatment. Arch Med Res 2008; 39:541-545.
37. Cua DJ, Tato CM. Innate IL-1 7-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10:479-489.
38. Zhang J, Ma D, Zhu X, et al. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica 2009; 94:1326-1329.
39. GuoZX, Chen ZP, Zheng CL, et al. The roleofTh17 cells in adult patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2009; 82:488-489.
40. Ma D, Zhu X, Zhao P, et al. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol 2008; 87:899-904.
41. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223:20-38.
42. Shan NN, Zhu XJ, Wang Q, et al. High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. Haematologica 2009; 94:1603-1607.
43. Shan NN, Zhu XJ, Peng J, et al. Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2009; 144:755-761.
44. Pan JL, Guan XR, Ma XH, He X. Expression of co-stimulatory molecules and role of interleukin 18 in peripheral lymphocytes of patients with idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 153:578-580.
45. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656-661.
46. Hamzeh-Cognasse H, Cognasse F, Palle S, et al. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunol 2008; 9:54-62.
47. KuwanaM,Okazaki Y, IkedaY. Splenic macrophages maintain the antiplatelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost 2009; 7:322-329.
48. Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009; 158:155-163.
49. Zhou Z, Chen Z, Li H, et al. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity 2009; 42:112-119.
50. Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 2009; 114:5362-5367.
51. Zhu XJ, Shi Y, Sun JZ, et al. High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia. J Clin Immunol 2009; 29:603-610.
52. Toffoletti E, Zaja F, Chiarvesio A, et al. No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy. Haematologica 2008; 93:795-796.
53. Martinez-Gamboa L, Mei H, Loddenkemper C, et al. Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombo cytopenia purpura. Clin Immunol 2009; 130:199-212.
54. Jin CQ, Liu F, Xiao H, et al. Correlation of lymphoblastic PPAR-gamma mRNA expression with plasma IL-13 contents in children with acute idiopathic thrombocytopenic purpura. Zhongguo Dangdai Erke Zazhi 2009; 11:367-370.
55. Suzuki T, Matsushima M, Shirakura K, et al. Association of inflammatory cytokine gene polymorphisms with platelet recovery in idiopathic thrombocytopenic purpura patients after the eradication of Helicobacter pylori. Digestion 2008; 77:73-78.
56. Satoh T, Pandey JP, Okazaki Y, et al. Single nucleotide polymorphism of interleukin-1beta associated with Helicobacter pylori infection in immune thrombocytopenic purpura. Tissue Antigens 2009; 73:353-357.
57. Zhao H, Du W, Wang D, et al. The expression of IFN-gamma, IL-4, Foxp3 and perforin genes are not correlated with DNA methylation status in patients with immune thrombocytopenic purpura. Platelets 2010; 21:137-143.
58. Zhao H, Du W, Wang D, et al. Single nucleotide polymorphism in the methyl-CpG binding domain 4 gene and the risk for immune thrombocytopenic purpura in Chinese population. Platelets 2010; 21:132-136.
59. Zhao H, Du W, Gu D, et al. DNMT3B 579G>T promoter polymorphism and the riskfor idiopathic thrombocytopenic purpura in a Chinese population. Acta Haematologica 2009; 122:31-35.
60. Tao J, Yang M, Chen Z, et al. Decreased DNA methyltransferase 3A and 3B mRNA expression in peripheral blood mononuclear cells and increased plasma SAH concentration in adult patients with idiopathic thrombocytopenic purpura. J Clin Immunol 2008; 28:432-439.
61. Chen Z, Zhou Z, Chen X, et al. Single nucleotide polymorphism in DNMT3B promoter and the risk for idiopathic thrombocytopenic purpura in Chinese population. J Clin Immunol 2008; 28:399-404.
62. Maia MH, Peixoto Rde L, de Lima CP, et al. Predisposition to idiopathic thrombocytopenic purpura maps close to the major histocompatibility complex class I chain-related gene A. Hum Immunol 2009; 70:179-183.
63. Xu J, Lu S, Tao J, et al. CD72 polymorphism associated with child-onset of idiopathic thrombocytopenic purpura in Chinese patients. J Clin Immunol 2008; 28:214-219.
64. Ma D, Dai J, Zhu X, et al. Aberrant expression of Notch signaling molecules in patients with immune thrombocytopenic purpura. Ann Hematol 2010; 89:155-161.
65. Soupir CP, Vergilio JA, Kelly E, et al. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Haematol 2009; 144:800-802.
66. Wang GB, Li CR, Li CG, et al. Expression and significance of BLyS/April in patients with acute idiopathic thrombocytopenic purpura. Chinese J Hematol 2008; 29:595-598.
67. Ren SM, Zhang CX, Li WC. Expression of T-bet and GATA3 in children with acute idiopathic thrombocytopenic purpura. Zhongguo Dangdai Erke Zazhi 2010; 12:29-31.
68. Dunoyer-Geindre S, Boehlen F, Favier R, et al. Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome. Haematologica 2008; 93:635-636.
69. Fontana V, Jy W, Ahn ER, et al. Increased procoagulant cell-derived micro-particles (C-MP) in splenectomized patients with ITP. Thromb Res 2008 122 599-603.
70. Perez-Simon JA, Tabera S, Sarasquete ME, et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 2009; 11:698-705.
71. Thachil J. Nitric oxide in immune thrombocytopenic purpura. Hematol 2009; 14:59-62.
72. Avramova B, Yordanova M, Heuft HG, et al. Transfer of donor immune thrombocytopenic purpura to a recipient of an allogeneic haematopoietic stem cell graft. Bone Marrow Transplant 2009; 44:203-204.
73. Dircks BH, Schuberth HJ, Mischke R. Underlying diseases and clinicopatho-logic variables of thrombocytopenic dogs with and without platelet-bound antibodies detected by use of a flow cytometric assay. J Am Vet Med Assoc 2009; 235:960-966.
74. Bianco D, Armstrong PJ, Washabau RJ. A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs. J Vet Int Med 2009; 23:1071-1078.